Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162443 | 1.00 | FFAR1 (0.45) | FFAR1FFAR4CYP19A1NR3C1PGR | |
| SCHEMBL8021406 | 0.85 | KIF11 (0.54) | CYP19A1PGRKIF11 | |
| SCHEMBL5317530 | 0.85 | FFAR1 (0.49) | FFAR1FFAR4CYP19A1NR3C1PGR | |
| SCHEMBL30339940 | 0.85 | FFAR1 (0.49) | FFAR1FFAR4CYP19A1NR3C1PGR | |
| SCHEMBL29738067 | 0.85 | FFAR1 (0.43) | FFAR1FFAR4CYP19A1NR3C1PGR | |
| SCHEMBL4242913 | 0.84 | MPO (0.43) | FFAR1FFAR4MPOCA12CA2 | |
| SCHEMBL8157286 | 0.82 | CA2 (0.43) | CYP19A1CA12CA2CA3CA6 | |
| SCHEMBL7770769 | 0.82 | FFAR1 (0.43) | FFAR1FFAR4CYP19A1NR3C1PGR | |
| SCHEMBL13608787 | 0.81 | CA2 (0.41) | CYP19A1CA12CA2CA3CA6 | |
| SCHEMBL23286837 | 0.80 | FFAR1 (0.40) | FFAR1FFAR4CYP19A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558491-A1 | METHODS AND INTERMEDIATES FOR PREPARING 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT | Pfizer Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-119585249-A | Process and intermediates for preparing 2- [ (4- {6- [ (4-cyano-2-fluorobenzyl) oxy ] pyridin-2-yl } piperidin-1-yl) methyl ] -1- [ (2S) -oxetan-2-ylmethyl ] -1H-benzimidazole-6-carboxylic acid, 1, 3-dihydroxy-2- (hydroxymethyl) propan-2-amine salt | 辉瑞公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2024018395-A1 | METHODS AND INTERMEDIATES FOR PREPARING 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT | PFIZER INC. (US) | 2024-01-25 | — | — | WO | claimed |
| CN-122055348-A | Process for the preparation of substituted phenylacetonitrile and substituted phenylacetic acid | 伊莱利利公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4558491-A1 | METHODS AND INTERMEDIATES FOR PREPARING 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT | Pfizer Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119896673-A | Application of GLP-1R agonist and metformin in preparation of drugs for treating diabetes and complications thereof | 深圳信立泰药业股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119874674-A | GLP-1R modulating compounds | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| CN-117242067-B | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119585249-A | Process and intermediates for preparing 2- [ (4- {6- [ (4-cyano-2-fluorobenzyl) oxy ] pyridin-2-yl } piperidin-1-yl) methyl ] -1- [ (2S) -oxetan-2-ylmethyl ] -1H-benzimidazole-6-carboxylic acid, 1, 3-dihydroxy-2- (hydroxymethyl) propan-2-amine salt | 辉瑞公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-114630823-B | GLP-1R Modulating Compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2022165076-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-114716423-A | 5, 6-dihydro-1, 2, 4-triazines and their pharmaceutical use as GLP-1 receptor agonists | 中国科学院上海药物研究所 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728940-A | GLP-1 receptor agonists and uses thereof | 日东制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-114630823-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022111624-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022109182-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-114478497-A | Aryl alkyl acids GLP-1 receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989972-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | FFAR1 85/4885FFAR4 100/4885CYP19A1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.